{"analyses":[{"ciLowerLimit":"0.96","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"3.38","estimateComment":"From the Cox Proportional hazard model with endocrine treatment fitted as a covariate. A hazard ratio \\> 1.0 indicates a higher average event rate and a shorter survival time for arimidex relative to tamoxifen.","groupDescription":"To determine the effect of anastrozole (AZ and AC) compared to tamoxifen (TZ and TC) in terms of overall survival. Overall survival is defined as the time from randomization to death from any cause.","groupIds":["OG000","OG001","OG002","OG003"],"nonInferiorityComment":"No multiplicity adjustment was applied.","nonInferiorityType":"SUPERIORITY","pValue":"0.07","paramType":"Cox Proportional Hazard","paramValue":"1.80","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Not applicable, estimates cannot be calculated due to too few events.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Not applicable, estimates cannot be calculated due to too few events.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Not applicable, estimates cannot be calculated due to too few events.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Not applicable, estimates cannot be calculated due to too few events.","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"450"},{"groupId":"OG001","value":"450"},{"groupId":"OG002","value":"453"},{"groupId":"OG003","value":"450"}],"units":"Participants"}],"description":"OS is defined as time from randomization to death from any cause","dispersionType":"Inter-Quartile Range","groups":[{"description":"Study Drugs Arimidex (Anastrozole), Zometa (Zoledronate; zoledronic acid)\n\nanastrozole: 1 mg/d\n\nzoledronic acid: 4 mg q6m\n\ngoserelin: 3.6 mg goserelin subcutaneously every 28 days","id":"OG000","title":"AZ (Arimidex+Zoledronate)"},{"description":"Study Drugs Nolvadex (Tamoxifen), Zometa (Zoledronate; zoledronic acid)\n\ntamoxifen: 20 mg/d\n\nzoledronic acid: 4 mg q6m\n\ngoserelin: 3.6 mg goserelin subcutaneously every 28 days","id":"OG001","title":"TZ (Tamoxifen+Zoledronate)"},{"description":"Study Drug Arimidex (Anastrozole)\n\nanastrozole: 1 mg/d\n\ngoserelin: 3.6 mg goserelin subcutaneously every 28 days","id":"OG002","title":"AC (Arimidex Control)"},{"description":"Study Drug Nolvadex (Tamoxifen)\n\ntamoxifen: 20 mg/d\n\ngoserelin: 3.6 mg goserelin subcutaneously every 28 days","id":"OG003","title":"TC (Tamoxifen Control)"}],"paramType":"MEDIAN","populationDescription":"Intent-to-treat population: All participants assigned to one of the four treatment arms were included in the analysis","reportingStatus":"POSTED","timeFrame":"Time from randomization to the analysis data cut-off date when 124 DFS events had occurred. On the analysis data cut-off date, maximum time on study per patient was 102 months.","title":"Comparison of Anastrozole vs Tamoxifen in Premenopausal Patients With Non-metastatic Breast Cancer With Respect to Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"years"}